Home > Insider Trading > Filing (0000899243-19-023936)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1773427	Springworks Therapeutics Inc.	SWTX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1578965	Adam Koppel	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1702957	Lawrence Jeffrey Schwartz	C/O Bain Capital Life Sciences Investors Llc, 200 Clarendon Street Boston MA 02116	Yes	No	Yes	No
1703031	Bain Capital Life Sciences Investors, Llc	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1786351	Bc Sw, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-09-17	6,078,103	$0.00	6,078,103	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2019-09-17	1,053,204	$0.00	7,131,307	No	4	C	Indirect	See Footnotes
Common Stock	Acquisiton	2019-09-17	150,000	$18.00	7,281,307	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnotes
No	4	C	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2019-09-17	6,078,103	$0.00	6,078,103	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2019-09-17	1,053,204	$0.00	1,053,204	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Each share of Series A Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series A Convertible Preferred Stock had no expiration date.
Each share of Series B Convertible Preferred Stock was convertible into shares of the Issuer's Common Stock on a 6.5810:1 basis. Upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock of the Issuer. The Series B Convertible Preferred Stock had no expiration date.
Represents shares purchased in the Issuer's initial public offering.
Represents shares held directly by BC SW, L.P.
Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC SW, L.P. As a result, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BC SW, L.P. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Jeffrey Schwartz is a director of the Issuer.